FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2511378889> ?p ?o ?g. }

• W2511378889 abstract "Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL).We investigated whether expression ratios of immunoproteasome to constitutive proteasome in leukaemic cells correlated with response to bortezomib-containing re-induction chemotherapy in patients with relapsed and refractory acute leukaemia, enrolled in two Children's Oncology Group phase 2 trials of bortezomib for ALL (COG-AALL07P1) and AML (COG-AAML07P1). Expression of proteasome subunits was examined in 72 patient samples (ALL n = 60, AML n = 12) obtained before start of therapy. Statistical significance between groups was determined by Mann-Whitney U test.Ratios of immunoproteasome to constitutive proteasome subunit expression were significantly higher in pre-B ALL cells than in AML cells for both β5i/β5 and β1i/β1 subunits (p = 0.004 and p < 0.001). These ratios correlated with therapy response in AML patients; β1i/β1 ratios were significantly higher (p = 0.028) between patients who did (n = 4) and did not reach complete remission (CR) (n = 8), although for β5i/β5 ratios, this did not reach significance. For ALL patients, the subunit ratios were also higher for patients who showed a good early response to therapy but this relation was not statistically significant. Overall, for this study, the patients were treated with combination therapy, so response was not only attributed to proteasome inhibition. Moreover, the leukaemic blast cells were not purified for these samples.These first ex vivo results encourage further studies into relative proteasome subunit expression to improve proteasome inhibition-containing therapy and as a potential indicator of bortezomib response in acute leukaemia." @default.
• W2511378889 created "2016-09-16" @default.
• W2511378889 creator A5005394469 @default.
• W2511378889 creator A5007946879 @default.
• W2511378889 creator A5023214494 @default.
• W2511378889 creator A5043037950 @default.
• W2511378889 creator A5061625014 @default.
• W2511378889 creator A5066861312 @default.
• W2511378889 creator A5067486820 @default.
• W2511378889 creator A5068689566 @default.
• W2511378889 creator A5070729528 @default.
• W2511378889 creator A5083129512 @default.
• W2511378889 creator A5083385949 @default.
• W2511378889 creator A5085057434 @default.
• W2511378889 creator A5088620010 @default.
• W2511378889 date "2016-09-06" @default.
• W2511378889 modified "2023-10-12" @default.
• W2511378889 title "Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy" @default.
• W2511378889 cites W104990378 @default.
• W2511378889 cites W135501746 @default.
• W2511378889 cites W1828610954 @default.
• W2511378889 cites W1963689482 @default.
• W2511378889 cites W1976015013 @default.
• W2511378889 cites W1976489571 @default.
• W2511378889 cites W1978735501 @default.
• W2511378889 cites W1983771472 @default.
• W2511378889 cites W1986036865 @default.
• W2511378889 cites W1988356885 @default.
• W2511378889 cites W1996891145 @default.
• W2511378889 cites W2009426416 @default.
• W2511378889 cites W2010163650 @default.
• W2511378889 cites W2024827262 @default.
• W2511378889 cites W2026642838 @default.
• W2511378889 cites W2043722634 @default.
• W2511378889 cites W2053728180 @default.
• W2511378889 cites W2055943754 @default.
• W2511378889 cites W2057652101 @default.
• W2511378889 cites W2066108468 @default.
• W2511378889 cites W2070962119 @default.
• W2511378889 cites W2077247713 @default.
• W2511378889 cites W2078328888 @default.
• W2511378889 cites W2085431272 @default.
• W2511378889 cites W2086634576 @default.
• W2511378889 cites W2093353574 @default.
• W2511378889 cites W2109590095 @default.
• W2511378889 cites W2113174807 @default.
• W2511378889 cites W2115219209 @default.
• W2511378889 cites W2116954006 @default.
• W2511378889 cites W2124631783 @default.
• W2511378889 cites W2135140338 @default.
• W2511378889 cites W2136504668 @default.
• W2511378889 cites W2140579395 @default.
• W2511378889 cites W2144466728 @default.
• W2511378889 cites W2147422161 @default.
• W2511378889 cites W2164481024 @default.
• W2511378889 cites W2166043738 @default.
• W2511378889 cites W2169249834 @default.
• W2511378889 cites W2398639705 @default.
• W2511378889 doi "https://doi.org/10.1186/s13045-016-0312-z" @default.
• W2511378889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5011854" @default.
• W2511378889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27599459" @default.
• W2511378889 hasPublicationYear "2016" @default.
• W2511378889 type Work @default.
• W2511378889 sameAs 2511378889 @default.
• W2511378889 citedByCount "23" @default.
• W2511378889 countsByYear W25113788892016 @default.
• W2511378889 countsByYear W25113788892017 @default.
• W2511378889 countsByYear W25113788892018 @default.
• W2511378889 countsByYear W25113788892019 @default.
• W2511378889 countsByYear W25113788892020 @default.
• W2511378889 countsByYear W25113788892021 @default.
• W2511378889 countsByYear W25113788892022 @default.
• W2511378889 countsByYear W25113788892023 @default.
• W2511378889 crossrefType "journal-article" @default.
• W2511378889 hasAuthorship W2511378889A5005394469 @default.
• W2511378889 hasAuthorship W2511378889A5007946879 @default.
• W2511378889 hasAuthorship W2511378889A5023214494 @default.
• W2511378889 hasAuthorship W2511378889A5043037950 @default.
• W2511378889 hasAuthorship W2511378889A5061625014 @default.
• W2511378889 hasAuthorship W2511378889A5066861312 @default.
• W2511378889 hasAuthorship W2511378889A5067486820 @default.
• W2511378889 hasAuthorship W2511378889A5068689566 @default.
• W2511378889 hasAuthorship W2511378889A5070729528 @default.
• W2511378889 hasAuthorship W2511378889A5083129512 @default.
• W2511378889 hasAuthorship W2511378889A5083385949 @default.
• W2511378889 hasAuthorship W2511378889A5085057434 @default.
• W2511378889 hasAuthorship W2511378889A5088620010 @default.
• W2511378889 hasBestOaLocation W25113788891 @default.
• W2511378889 hasConcept C126322002 @default.
• W2511378889 hasConcept C143998085 @default.
• W2511378889 hasConcept C203014093 @default.
• W2511378889 hasConcept C27740335 @default.
• W2511378889 hasConcept C2776364478 @default.
• W2511378889 hasConcept C2776694085 @default.
• W2511378889 hasConcept C2777478702 @default.
• W2511378889 hasConcept C2778367456 @default.
• W2511378889 hasConcept C2993296363 @default.
• W2511378889 hasConcept C535046627 @default.
• W2511378889 hasConcept C71924100 @default.
• W2511378889 hasConcept C86803240 @default.

• next